NeuBase Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Other Prepaid Expenses and Other Current Assets

12 Months Ended

Sep. 30, 2021

4. Other Prepaid Expenses and Other Current Assets

The Company’s prepaid expenses and other current assets consisted of the following:


	As of September 30,		As of September 30,
	2021		2020
Prepaid research and development expense	$	583,267	$	205,641
Prepaid rent		172,518		—
Other prepaid expenses and other current assets		780,401		88,999
Total	$	1,536,186	$	294,640